KR100808149B1 - 정제된 ｌｈ - Google Patents
정제된 ｌｈ Download PDFInfo
- Publication number
- KR100808149B1 KR100808149B1 KR1020027010624A KR20027010624A KR100808149B1 KR 100808149 B1 KR100808149 B1 KR 100808149B1 KR 1020027010624 A KR1020027010624 A KR 1020027010624A KR 20027010624 A KR20027010624 A KR 20027010624A KR 100808149 B1 KR100808149 B1 KR 100808149B1
- Authority
- KR
- South Korea
- Prior art keywords
- column
- hlh
- delete delete
- luteinizing hormone
- exchange chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010073521 Luteinizing Hormone Proteins 0.000 claims abstract description 49
- 102000009151 Luteinizing Hormone Human genes 0.000 claims abstract description 49
- 229940040129 luteinizing hormone Drugs 0.000 claims abstract description 49
- 238000004007 reversed phase HPLC Methods 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 22
- 238000000746 purification Methods 0.000 claims abstract description 21
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims abstract description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 66
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 18
- 239000005695 Ammonium acetate Substances 0.000 claims description 18
- 229940043376 ammonium acetate Drugs 0.000 claims description 18
- 235000019257 ammonium acetate Nutrition 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 15
- 229920002271 DEAE-Sepharose Polymers 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 6
- 239000012614 Q-Sepharose Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 abstract description 16
- 239000005556 hormone Substances 0.000 abstract description 16
- 239000000356 contaminant Substances 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 7
- 239000006228 supernatant Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 24
- 238000000108 ultra-filtration Methods 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000008215 water for injection Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 8
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 8
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 8
- 239000001099 ammonium carbonate Substances 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 102000006771 Gonadotropins Human genes 0.000 description 7
- 108010086677 Gonadotropins Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000002622 gonadotropin Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 239000004264 Petrolatum Substances 0.000 description 5
- 239000012506 Sephacryl® Substances 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940066842 petrolatum Drugs 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- 108010057021 Menotropins Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002095 exotoxin Substances 0.000 description 3
- 231100000776 exotoxin Toxicity 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940094892 gonadotropins Drugs 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- -1 anionic oligosaccharides Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001592 luteinising effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 241000208140 Acer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000122202 Haynaldia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PXSOOFLAIBKMKO-UHFFFAOYSA-K O.O.P(=O)([O-])([O-])[O-].[Na+].[Na+].O.P(=O)(O)(O)O.[Na+] Chemical compound O.O.P(=O)([O-])([O-])[O-].[Na+].[Na+].O.P(=O)(O)(O)O.[Na+] PXSOOFLAIBKMKO-UHFFFAOYSA-K 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Semiconductor Lasers (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00103692 | 2000-02-22 | ||
| EP00103692.0 | 2000-02-22 | ||
| PCT/EP2001/000666 WO2001062774A2 (en) | 2000-02-22 | 2001-01-22 | Purified lh |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030001358A KR20030001358A (ko) | 2003-01-06 |
| KR100808149B1 true KR100808149B1 (ko) | 2008-02-29 |
Family
ID=8167926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027010624A Expired - Lifetime KR100808149B1 (ko) | 2000-02-22 | 2001-01-22 | 정제된 ｌｈ |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7053054B2 (enExample) |
| EP (2) | EP1261622B1 (enExample) |
| JP (1) | JP4959898B2 (enExample) |
| KR (1) | KR100808149B1 (enExample) |
| CN (1) | CN100480258C (enExample) |
| AT (1) | ATE356138T1 (enExample) |
| AU (1) | AU780377B2 (enExample) |
| BG (1) | BG65761B1 (enExample) |
| BR (2) | BR122012018280B8 (enExample) |
| CA (1) | CA2399100C (enExample) |
| CY (1) | CY1108056T1 (enExample) |
| CZ (1) | CZ303274B6 (enExample) |
| DE (1) | DE60127100T2 (enExample) |
| DK (1) | DK1261622T3 (enExample) |
| EA (1) | EA004385B1 (enExample) |
| EE (1) | EE04932B1 (enExample) |
| ES (1) | ES2278722T3 (enExample) |
| HR (1) | HRP20020651B1 (enExample) |
| HU (1) | HU227007B1 (enExample) |
| IL (2) | IL151309A0 (enExample) |
| MX (1) | MXPA02007867A (enExample) |
| NO (1) | NO328693B1 (enExample) |
| PL (1) | PL207728B1 (enExample) |
| PT (1) | PT1261622E (enExample) |
| RS (1) | RS50416B (enExample) |
| SI (1) | SI1261622T1 (enExample) |
| SK (1) | SK287041B6 (enExample) |
| UA (2) | UA78676C2 (enExample) |
| WO (1) | WO2001062774A2 (enExample) |
| ZA (1) | ZA200206108B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227007B1 (en) * | 2000-02-22 | 2010-04-28 | Serono Lab | Purified lh |
| DE10235168A1 (de) * | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| US10105417B2 (en) | 2003-03-04 | 2018-10-23 | Aspenbio Pharma, Inc. | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
| CN1283792C (zh) * | 2003-11-14 | 2006-11-08 | 余伟明 | 生物大分子组分相分离法 |
| AU2004309040B2 (en) * | 2003-12-22 | 2010-12-16 | Ares Trading S.A. | Method for purifying FSH |
| ATE469912T1 (de) * | 2004-10-04 | 2010-06-15 | Novetide Ltd | Gegenionenaustauschverfahren für peptide |
| ATE408624T1 (de) * | 2004-11-09 | 2008-10-15 | Ares Trading Sa | Verfahren zur reinigung von fsh |
| CN101282990B (zh) | 2005-08-26 | 2013-04-03 | 阿雷斯贸易股份有限公司 | 糖基化干扰素-β的制备方法 |
| EP1960419B1 (en) | 2005-12-09 | 2016-03-16 | Ares Trading S.A. | Method for purifying fsh or a fsh mutant |
| US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
| AU2008314689A1 (en) * | 2007-10-22 | 2009-04-30 | Merck Serono S.A. | Method for purifying an Fc-containing protein |
| CN101928342B (zh) * | 2009-06-18 | 2013-05-08 | 上海天伟生物制药有限公司 | 一种高纯度绝经期促性腺素及其制备方法和用途 |
| WO2015168622A1 (en) * | 2014-05-01 | 2015-11-05 | Virginia Tech Intellectual Properties, Inc. | Keratin nanomaterials and methods of production |
| CN104569441B (zh) * | 2015-01-19 | 2016-02-03 | 成都大熊猫繁育研究基地 | 大熊猫尿液促黄体素的酶联检测方法及其应用 |
| EP3969026A1 (en) | 2019-05-16 | 2022-03-23 | Ceva Santé Animale | Compositions and methods for increasing reproduction performance in non human mammals using recombinant luteinizing hormone |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002757A1 (en) * | 1988-09-02 | 1990-03-22 | Integrated Genetics, Inc. | Heteropolymeric protein |
| WO1990009800A1 (en) * | 1989-02-21 | 1990-09-07 | Washington University | Modified forms of reproductive hormones |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087615A (en) * | 1989-03-17 | 1992-02-11 | Applied Research Systems Ars Holding N.V. | Novel method of ovulation induction in humans |
| IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
| IT1287138B1 (it) * | 1996-11-07 | 1998-08-04 | Ibsa Inst Biochimique Sa | Procedimento per la separazione e purificazione di fsh e lh |
| TW518235B (en) * | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
| EP0996629B1 (en) * | 1997-06-25 | 2006-08-02 | Applied Research Systems Ars Holding N.V. | Disulfide crosslinked glycoprotein hormone analogs, their preparation and use |
| HU227007B1 (en) * | 2000-02-22 | 2010-04-28 | Serono Lab | Purified lh |
-
2001
- 2001-01-22 HU HU0301814A patent/HU227007B1/hu unknown
- 2001-01-22 DE DE60127100T patent/DE60127100T2/de not_active Expired - Lifetime
- 2001-01-22 HR HR20020651A patent/HRP20020651B1/xx not_active IP Right Cessation
- 2001-01-22 UA UA2002086889A patent/UA78676C2/xx unknown
- 2001-01-22 PL PL362891A patent/PL207728B1/pl unknown
- 2001-01-22 RS YUP-603/02A patent/RS50416B/sr unknown
- 2001-01-22 CZ CZ20022856A patent/CZ303274B6/cs not_active IP Right Cessation
- 2001-01-22 BR BR122012018280A patent/BR122012018280B8/pt not_active IP Right Cessation
- 2001-01-22 CA CA2399100A patent/CA2399100C/en not_active Expired - Fee Related
- 2001-01-22 BR BRPI0108553A patent/BRPI0108553B8/pt not_active IP Right Cessation
- 2001-01-22 AT AT01907476T patent/ATE356138T1/de active
- 2001-01-22 DK DK01907476T patent/DK1261622T3/da active
- 2001-01-22 JP JP2001562555A patent/JP4959898B2/ja not_active Expired - Lifetime
- 2001-01-22 AU AU35436/01A patent/AU780377B2/en not_active Expired
- 2001-01-22 ES ES01907476T patent/ES2278722T3/es not_active Expired - Lifetime
- 2001-01-22 EE EEP200200464A patent/EE04932B1/xx unknown
- 2001-01-22 EP EP01907476A patent/EP1261622B1/en not_active Expired - Lifetime
- 2001-01-22 PT PT01907476T patent/PT1261622E/pt unknown
- 2001-01-22 KR KR1020027010624A patent/KR100808149B1/ko not_active Expired - Lifetime
- 2001-01-22 EP EP06016629A patent/EP1777231A3/en not_active Withdrawn
- 2001-01-22 SI SI200130709T patent/SI1261622T1/sl unknown
- 2001-01-22 MX MXPA02007867A patent/MXPA02007867A/es active IP Right Grant
- 2001-01-22 WO PCT/EP2001/000666 patent/WO2001062774A2/en not_active Ceased
- 2001-01-22 EA EA200200893A patent/EA004385B1/ru not_active IP Right Cessation
- 2001-01-22 US US10/204,554 patent/US7053054B2/en not_active Expired - Lifetime
- 2001-01-22 UA UAA200612399A patent/UA92145C2/uk unknown
- 2001-01-22 CN CNB018053645A patent/CN100480258C/zh not_active Expired - Lifetime
- 2001-01-22 SK SK1205-2002A patent/SK287041B6/sk not_active IP Right Cessation
- 2001-01-22 IL IL15130901A patent/IL151309A0/xx unknown
-
2002
- 2002-07-31 ZA ZA200206108A patent/ZA200206108B/en unknown
- 2002-08-14 BG BG107001A patent/BG65761B1/bg unknown
- 2002-08-18 IL IL151309A patent/IL151309A/en active IP Right Grant
- 2002-08-20 NO NO20023963A patent/NO328693B1/no not_active IP Right Cessation
-
2005
- 2005-11-28 US US11/287,341 patent/US20060079460A1/en not_active Abandoned
-
2007
- 2007-05-10 CY CY20071100638T patent/CY1108056T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990002757A1 (en) * | 1988-09-02 | 1990-03-22 | Integrated Genetics, Inc. | Heteropolymeric protein |
| WO1990009800A1 (en) * | 1989-02-21 | 1990-09-07 | Washington University | Modified forms of reproductive hormones |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100808149B1 (ko) | 정제된 ｌｈ | |
| RS60302B1 (sr) | Inhibitori bromodomena | |
| CN100482679C (zh) | 人绒毛膜促性腺激素的纯化方法 | |
| US7022822B1 (en) | Highly purified gonadotropin compositions and process for preparing them | |
| HK1052014B (en) | Purified lh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20020814 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20051124 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061031 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070531 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20071130 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20070531 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20061031 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20071226 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20071130 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20080131 Appeal identifier: 2007101012930 Request date: 20071226 |
|
| N234 | Change of applicant [patent]: notification of change of applicant and registration of full transfer of right | ||
| PN2301 | Change of applicant |
Patent event date: 20080118 Comment text: Notification of Change of Applicant and Registration of Full Transfer of Right Patent event code: PN23012R02D |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20071226 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20071226 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20070727 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20061228 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20080131 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20080128 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20080221 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20080222 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20110208 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120207 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20130130 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130130 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20140204 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140204 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20150120 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150120 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160119 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170119 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20180202 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180202 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20190130 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190130 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20200205 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200205 Start annual number: 13 End annual number: 13 |
|
| PC1801 | Expiration of term |
Termination date: 20210722 Termination category: Expiration of duration |